By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Some of the worst terrorists in the world might not be as reviled in America as the man who made a perp walk today.
If smug were a felony, Martin Shkreli would've made the stroll months ago, after he bought the rights to Daraprim, which treated toxoplasmosis, a deadly illness for unborn babies and patients with compromised immune systems including those with HIV or cancer. Then he raised the raised the $14 price to $750 per pill. There was money to be made and he aimed to make it. He showed not an ounce of shame or remorse for doing so at the expense of the vulnerable.
Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is escorted by law enforcement agents in New York Thursday, Dec. 17, 2015, after being taken into custody following a securities probe. A seven-count indictment unsealed in Brooklyn federal court Thursday charged Shkreli with conspiracy to commit securities fraud, conspiracy to commit wire fraud and securities fraud. (AP Photo/Craig Ruttle)
True, in the eyes of the law, he's still an innocent man.
But still, $750 was the price of our sympathy.
NEW YORK, NY - DECEMBER 17: Martin Shkreli (2nd R), CEO of Turing Pharmaceutical, is brought out of 26 Federal Plaza by law enforcement officials after being arrested for securities fraud on December 17, 2015 in New York City. Shkreli gained notoriety earlier this year for raising the price of Daraprim, a medicine used to treat the parasitic condition of toxoplasmosis, from $13.50 to $750 though the arrest that happened early this morning does not involve that price hike. (Photo by Andrew Burton/Getty Images)
Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is belted into an awaiting car after being taken into custody following a securities probe, on Thursday, Dec. 17, 2015 in New York. A seven-count indictment unsealed in Brooklyn federal court Thursday charged Shkreli with conspiracy to commit securities fraud, conspiracy to commit wire fraud and securities fraud. (AP Photo/Craig Ruttle)
Turn Up Your Support
MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all.
